How Amicus Therapeutics Is Revolutionizing the Biopharmaceutical Industry

Amicus Therapeutics is a government biopharmaceutical firm, which is regarded as the origin of innovative therapies. It treats a group of deadly rare and orphaned diseases commonly known as lysosomal storage disorders. It is located in Cranbury, NJ and has a brilliant way of addressing a broad range of human genetic diseases. The company started in the year 2007.


The firms main achievement is a product called Migalastat a pharmacological chaperone treatment to cure Fabry disorder that focuses on stabilizing endogenous mutant alpha-galactosidase. Before the starting of migalastat monotherapy, the organization got involved in an alliance with GlaxoSmithKline and JCR Pharmaceuticals to inspect co-formulation with recombinant alpha-galactosidase.


Amicus Therapeutics expanded from a single location to having another study station in San Diego in the year 2008. In the year 2010, the organization was given a grant of US$500,000 from The Michael J. Fox Foundation to boost research carried out in association with David Geffen School of Medicine at UCLA. Amicus Therapeutics also got a US$210,300 from Alzheimer’s Drug Discovery Foundation to assisted pre-clinical work in partnership with Icahn School of Medicine at Mount Sinai via Alzheimer’s disease Research Center.


The role of the Manager is developing the firm’s vision ( The vision is derived from unique science, setting priorities, and employing skilled and professional people from all over the Globe. Amicus Therapeutics works with a commitment to their clients, which helps in focusing on quality and compliance.


All the staff at Amicus Therapeutics is dedicated and skilled to deliver quality work with intelligence. The strong inspiration comes from their bosses and board of directions as well as their ability to form a good friendship with one another.


The colleagues always help each other in the common understanding of the companies’ vision. This happens in all departments. The teamwork and togetherness are critical in making Amicus successful (Indeed).


In November 2013, Amicus Therapeutics took over Callidus Biopharma, hence gaining resources and intellectual properties for treatment of Pompe sickness. Two years later, Amicus Therapeutics acquired Scioderm for up to $947 million in cash and stock.

More at